Exhibit 99.1


Marrone Bio Innovations, Inc. Reports First Quarter 2020 Financial Results


Seventh Consecutive Quarter of Year Over Year Revenue Growth Realized in Challenging Environment for Agricultural Production


Record Gross Margins Mark Sixth Consecutive Quarter of 50+ Percent Performance


DAVIS, Calif. – May 11, 2020 – Marrone Bio Innovations, Inc. (NASDAQ: MBII) (“Marrone Bio” or the “Company”), an international leader in sustainable bioprotection and plant health solutions

, has provided its financial results for the first quarter ended March 31, 2020.


Selected Operating and Financial Highlights


$ in millions 




   % Increase (Decrease) 
Revenues  $9.7   $8.7    11%
Gross Profit  $5.6   $5.0    12%
Gross Margin   57.7%   57.2%   +50bps 
Operating Expenses  $11.2   $8.6    30%
Net Loss  $(7.0)  $(3.9)   79%
Adjusted EBITDA1  $(3.7)  $(2.6)   42%
Cash Used in Operations  $(6.3)  $(7.7)   (18)%


1)Adjusted EBITDA is a non-GAAP financial measure and is described in relation to its most directly comparable GAAP measure under “Use of Non-GAAP Financial Information” below.


First Quarter 2020 Financial Summary


First quarter 2020 revenues increased 11 percent to $9.7 million. Key sales for the quarter included Venerate® for foliar applications in the vegetable and stone fruit markets, and the introduction of Stargus® biofungicide in California. Sales of Regalia® in almond and tree fruit crops continued to grow, as a result of our successful BioUnite program.
Gross margins of 57.7 percent in the first quarter were a new record, marking the company’s sixth consecutive quarter of gross margins of 50+ percent.
Operating expenses in the first quarter of 2020 were $11.2 million, up $2.6 million from the first quarter of 2019. Of the increase, $0.9 million was non-cash, including a $0.6 million non-cash amortization charge, as well as stock compensation expenses. In addition, $1.1 million of the increase was due to the addition of Pro Farm’s operating expenses.
Net loss in the first quarter of 2020 was $7.0 million, a year-over-year increase of $3.1 million. The increase included $1.4 million in a non-cash charge related to the estimated fair value of warrants, $0.6 million in non-cash amortization charges associated with the acquisition of Pro Farm, a $0.3 million increase in non-cash stock compensation expenses and the $1.1 million addition of Pro Farm’s operating expenses, partially offset by increased gross profit.
Adjusted EBITDA increased to a $3.7 million loss in the first quarter of 2020, from a $2.6 million loss in the first quarter of 2019, a $1.1 million difference. The increase was primarily due to the addition of Pro Farm’s operating expenses. Adjusted EBITDA is further described under “Use of Non-GAAP Financial Information” below.
Cash used in operations was $6.3 million in the first quarter of 2020 as compared to $7.7 million in the first quarter of 2019.





Management Commentary


“Farmers around the world are working tirelessly to ensure a safe and adequate food supply as they adjust to the changes brought on by the COVID-19 pandemic,” said Dr. Pam Marrone, Chief Executive Officer of Marrone Bio Innovations. “Growers remain focused on the task at hand: harvesting early crops, planting, increasing farm worker protection and adjusting to the changing demand from retail and food service.


“We are pleased with the progress we have made with the Pro Farm integration and continue to find exciting synergies, where both Marrone Bio and Pro Farm benefit from leveraging our existing partner relationships to expand geographically and create new product combinations. While we have seen year-over-year revenue growth in the first quarter of 2020 in part due to the addition of Pro Farm’s seed treatments, we expect greater growth for the remainder of 2020, notwithstanding the impact of COVID-19.”


“As an essential business, we are fortunate to continue to provide our grower customers with necessary crop protection and plant health tools. However, we anticipate continued challenges to the agricultural economy through the remainder of the year. In an uncertain environment, we have taken steps to reduce costs while retaining our workforce,” concluded Marrone.


Jim Boyd, Chief Financial Officer of Marrone Bio Innovations, added “Subsequent to the end of the quarter, two events took place that significantly reduced our business risk and strengthened our balance sheet. First, we applied for and received a $1.7 million loan under the Paycheck Protection Program as part of the Coronavirus Aid, Relief and Economic Security Act, which has helped us to maintain our workforce in the face of economic uncertainty. Second, we signed a warrant exchange agreement with existing institutional investors that provided $2.5 million in financing earlier this month, and that, if exercised in full, would result in up to $20 million in additional proceeds, which we expect would take us to an Adjusted EBITDA breakeven level of operations given our current outlook and plan.”






Operational Highlights


  The company signed a commercial agreement with Anasac Chile S.A. to develop and distribute Grandevo® and Venerate® bioinsecticides in Chile, as well as an additional agreement with UPL South Africa Ltd. to distribute Regalia Maxx, both significant export markets.
  Jet-Oxide® 15% post-harvest sanitizer and industrial disinfectant product is now approved by the U.S. Environmental Protection Agency (“EPA”) for use against human coronaviruses to sanitize industrial food and agricultural hard surfaces.
  Pacesetter™, a recently EPA-approved bio-based plant health product, is now available to corn, soybean, wheat and other row crop growers in the United States. In our BioUnite program, Pacesetter acts synergistically with conventional fungicides, increasing yield by up to seven bushels per acre in soybeans and 13 bushels per acre in corn.
  The company submitted registration for Stargus, its second biofungicide product, for use in the European Union, the second largest global fungicide market.


Conference Call and Webcast


Management will host an investor conference call today, May 11, 2020, at 1:30 p.m. PDT (4:30 p.m. EDT) to discuss Marrone Bio Innovations’ 2020 first quarter financial results. The call will conclude with a Q&A from participants. To participate, please use the following information:


Q1 2020 Conference Call and Webcast

Date: Monday, May 11, 2020

Time: 1:30 p.m. Pacific time (4:30 p.m. Eastern time)

U.S. Dial-in: 1-800-347-6311

International Dial-in: 1-323-994-2132

Conference ID: 3011305

Webcast: http://public.viavid.com/index.php?id=139111


Please dial in at least 10 minutes before the start of the call to ensure timely participation.


A playback of the call will be available through June 11, 2020. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally. Please use the replay pin number 3011305. A webcast will also be available for 30 days on the IR section of the Marrone Bio Innovations website or by clicking here: http://public.viavid.com/index.php?id=139111.





About Marrone Bio Innovations


Marrone Bio Innovations Inc. (NASDAQ: MBII) is a growth-oriented company leading the movement to a more sustainable world through the discovery, development and sale of innovative biological products for crop protection, plant health and waterway systems treatment that help customers operate more sustainably while increasing their return on investment. MBI has screened over 18,000 microorganisms and 350 plant extracts, leveraging its in-depth knowledge of plant and soil microbiomes enhanced by advanced molecular technologies and natural product chemistry to rapidly develop seven product lines. Supported by a robust portfolio of over 400 issued and pending patents, MBI’s currently available commercial products are Regalia®, Stargus®, Grandevo®, Venerate®, Majestene®, Haven®, Pacesetter™, Zelto® Jet Oxide® and Jet Ag® and Zequanox®, with a next-generation insecticide-nematicide, a breakthrough bioherbicide and a biofumigant in the Company’s product pipeline. MBI’s Pro Farm Finland-based subsidiary employs a proprietary technology derived from wood waste to stimulate plant growth and improve plant health, resulting in improved yields and crop quality. Products include UBP™ 110, Foramin®, UBP™ Seed Treatment, Foramin® ST.


Learn more about Marrone Bio Innovations at www.marronebio.com. We also use our investor relations website, https://investors.marronebio.com, as well as our corporate Twitter account, @Marronebio, as means of disclosing material non-public information, and encourage our investors and others to monitor and review the information we make public in these locations. Follow us on social media: Twitter, LinkedIn and Instagram.


Use of Non-GAAP Financial Information

This earnings release discusses Adjusted EBITDA, which is not a financial measure as defined by generally accepted accounting principles in the United States (GAAP). This financial measure is presented as a supplemental measure of operating performance because we believe it can aid in, and enhance, the understanding of our financial results. In addition, we use Adjusted EBITDA as a measure internally for budgeting purposes. We define Adjusted EBITDA as net income (loss) before (1) interest expense (income), net, (2) income tax expense (benefit), (3) depreciation, (4) amortization of intangible assets, (5) stock-based compensation expense, and (6) from time to time, certain specific transaction-related costs and other non-cash charges related to debt and equity instruments.


Other companies may define or calculate this measure differently, limiting the usefulness as a comparative measure. Because of this limitation, this non-GAAP financial measure should not be considered in isolation or as a substitute for or superior to performance measures calculated in accordance with GAAP and should be read in conjunction with the financial statement tables.





GAAP to Non-GAAP Reconciliation


   MARCH 31, 
   2020   2019 
Net Loss  $(7,024)  $(3,917)
Taxes   34    - 
Interest Expense   337    306 
Depreciation and amortization   891    455 
Stock based compensation   907    558 
Loss on issuance of new warrants   1,391    - 
Change in fair value of contingent consideration to Pro Farm shareholders   (237)   - 
Adjusted EBITDA  $(3,701)  $(2,598)


Marrone Bio Innovations Forward Looking Statements


This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing MBI’s views as of any subsequent date. Examples of such statements include statements regarding the Company’s future financial results and revenue growth, future adoption of the Company’s products, including growth in seed treatment sales, the potential benefits of recent acquisitions and the Company’s products, and the potential future exercise of the Company’s warrants. Such forward-looking statements are based on information available to the Company as of the date of this release and involve a number of risks and uncertainties, some beyond the Company’s control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including the recent uncertainty in the global economy and industry-specific economy caused by the COVID-19 pandemic, consumer, regulatory and other factors affecting demand for the Company’s products, any difficulty in marketing MBI’s products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, adverse decisions by regulatory agencies and other relevant third parties and any difficulty in integrating the acquired Pro Farm, Jet-Ag and Jet-Oxide businesses. Additional information that could lead to material changes in MBI’s performance is contained in its filings with the Securities and Exchange Commission. MBI is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this release, whether as a result of new information, future events or otherwise.


Marrone Bio Innovations Contacts:

Pam Marrone, CEO and Founder

Jim Boyd, President and CFO

Telephone: +1 (530) 750-2800

Email: Info@marronebio.com


Investor Relations:

Greg Falesnik

Managing Director

MZ Group – MZ North America

Main: 949-385-6449







Condensed Consolidated Balance Sheets

(In Thousands, Except Par Value)


   MARCH 31,   DECEMBER 31, 
   2020   2019 
Current assets:          
Cash and cash equivalents  $10,120   $6,252 
Accounts receivable   10,417    5,925 
Inventories, net   7,077    8,149 
Prepaid expenses and other current assets   1,812    1,390 
Total current assets   29,426    21,716 
Property, plant and equipment, net   13,184    13,260 
Right of use assets, net   4,361    4,567 
Intangible assets, net   23,254    23,842 
Goodwill   6,740    6,764 
Restricted cash   1,560    1,560 
Other assets   867    1,008 
Total assets  $79,392   $72,717 
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable  $6,509   $3,379 
Accrued liabilities   11,175    12,467 
Deferred revenue, current portion   450    427 
Lease liability, current portion   933    913 
Debt, current portion, net   8,917    3,899 
Total current liabilities   27,984    21,085 
Deferred revenue, less current portion   1,882    1,986 
Lease liability, less current portion   3,742    3,970 
Debt, less current portion, net   11,635    11,847 
Debt due to related parties   7,300    7,300 
Other liabilities   1,984    2,971 
Total liabilities   54,527    49,159 
Commitments and contingencies          
Stockholders’ equity:          
Preferred stock: $0.00001 par value; 20,000 shares authorized and no shares issued or outstanding at March 31, 2020 and December 31, 2019        
Common stock: $0.00001 par value; 250,000 shares authorized, 145,541 and 139,526 shares issued and outstanding as of March 31, 2020 and December 31, 2019   1    1 
Additional paid in capital   352,536    344,206 
Accumulated deficit   (327,672)   (320,649)
Total stockholders’ equity   24,865    23,558 
Total liabilities and stockholders’ equity  $79,392   $72,717 






Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Amounts)






   2020   2019 
Product  $9,535   $8,601 
License   115    115 
Total revenues   9,650    8,716 
Cost of product revenues   4,081    3,729 
Gross profit   5,569    4,987 
Operating Expenses:          
Research, development and patent   3,234    2,942 
Selling, general and administrative   7,993    5,674 
Total operating expenses   11,227    8,616 
Loss from operations   (5,658)   (3,629)
Other (expense) income:          
Interest expense   (337)   (306)
Loss on issuance of August 2019 warrants   (1,391)    
Change in fair value of contingent consideration   237     
Other income, net   159    18 
Total other (expense) income, net   (1,332)   (288)
Loss before taxes   (6,990)   (3,917)
Income tax expense   (34)    
Net loss  $(7,024)  $(3,917)
Basic and diluted net loss per common share:  $(0.05)  $(0.04)
Weighted-average shares outstanding used in computing basic and diluted net loss per common share:   141,572    110,691 






Condensed Consolidated Statements of Cash Flows

(In Thousands)


   2020   2019 
Cash flows from operating activities          
Net loss  $(7,024)  $(3,917)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   891    455 
Gain on disposal of equipment   (9)    
Right of use assets amortization   206    199 
Share-based compensation   907    558 
Non-cash interest expense   61    73 
Loss on issuance of August 2019 warrants   1,391     
Change in fair value of contingent consideration   (237)    
Net changes in operating assets and liabilities:          
Accounts receivable   (4,492)   (6,039)
Inventories   1,072    670 
Prepaid Expenses and other assets   (281)   (336)
Accounts payable   3,068    726 
Accrued and other liabilities   (1,500)   310 
Lease Liability   (208)   (150)
Deferred revenue   (137)   (199)
Net cash used in operating activities   (6,292)   (7,650)
Cash flows from investing activities          
Payment of future contingent consideration in connection with previous asset purchase   (540)    
Sale of property, plant, equipment   2     
Purchases of property, plant and equipment   (135)   (116)
Net cash used in investing activities   (673)   (116)
Cash flows from financing activities          
Proceeds from secured borrowings   11,319    6,714 
Reductions in secured borrowings   (6,322)   (3,511)
Financing costs   (64)    
Exercise of stock options   12     
Proceeds from employee stock purchase plan   84     
Exercise of warrants   6,000     
Repayment of debt   (196)   (72)
Net cash provided by financing activities   10,833    3,131 
Net (decrease) increase in cash and cash equivalents and restricted cash   3,868    (4,635)
Cash and cash equivalents and restricted cash, beginning of period   7,812    19,781 
Cash and cash equivalents and restricted cash, end of period  $11,680   $15,146 
Supplemental disclosure of cash flow information          
Cash paid for interest  $269   $223 
Supplemental disclosure of non-cash investing and financing activities          
Property, plant and equipment included in accounts payable and accrued liabilities  $93   $10 




View differences made from one to another to evaluate Marrone Bio Innovations Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Marrone Bio Innovations Inc.


Never Miss A New SEC Filing Again

Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.


We Highlighted This SEC Filing For You

SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.


Widen Your SEC Filing Reading Experience

Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view


Uncover Actionable Information Inside SEC Filings

SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q


Adobe PDF, Microsoft Word and Excel Downloads

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis


FREE Financial Statements

Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator

Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not


Financial Stability Report

Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity


Log in with your credentials


Forgot your details?

Create Account